Jundishapur Journal of Chronic Disease Care

Published by: Kowsar

A Review on Clinical Pharmacokinetics of Tamsulosin in Patients with Benign Prostatic Hyperplasia

Zahra Tolou Ghamari 1 , * and Hamid Mazdak 2
Authors Information
1 Isfahan Kidney Transplantation Research Center, Alzahra Research Center, Isfahan University of Medical Sciences, Isfahan, IR Iran
2 Department of Urology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, IR Iran
Article information
  • Jundishapur Journal of Chronic Disease Care: January 2017, 6 (1); e38794
  • Published Online: August 29, 2016
  • Article Type: Review Article
  • Received: April 27, 2016
  • Revised: May 11, 2016
  • Accepted: May 15, 2016
  • DOI: 10.17795/jjcdc-38794

To Cite: Tolou Ghamari Z, Mazdak H. A Review on Clinical Pharmacokinetics of Tamsulosin in Patients with Benign Prostatic Hyperplasia, Jundishapur J Chronic Dis Care. 2017 ; 6(1):e38794. doi: 10.17795/jjcdc-38794.

Abstract
Copyright © 2016, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Acknowledgements
Footnotes
References
  • 1. La Vignera S, Condorelli RA, Russo GI, Morgia G, Calogero AE. Endocrine control of benign prostatic hyperplasia. Andrology. 2016; 4(3): 404-11[DOI][PubMed]
  • 2. Food and Drug Administration (FDA), . FDA approves first generic tamsulosin to treat enlarged prostate gland (Press release) 2010;
  • 3. Michel MC, Korstanje C, Krauwinkel W, Kuipers M. The pharmacokinetic profile of tamsulosin oral controlled absorption system (OCAS®). Eur Urol Supplement. 2005; 4(2): 15-24
  • 4. Tsuda Y, Tatami S, Yamamura N, Tadayasu Y, Sarashina A, Liesenfeld KH, et al. Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder. Br J Clin Pharmacol. 2010; 70(1): 88-101[DOI][PubMed]
  • 5. Price D. Potential mechanisms of action of superselective alpha(1)-adrenoceptor antagonists. Eur Urol. 2001; 40 Suppl 4: 5-11[PubMed]
  • 6. Djavan B, Handl MJ, Dianat S. Combined medical treatment using dutasteride and tamsulosin for lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Expert Opin Pharmacother. 2010; 11(15): 2535-47[DOI][PubMed]
  • 7. Yoshida M, Inadome A, Masunaga K, Nagata T, Yoshiyasu T. Effectiveness of tamsulosin hydrochloride and its mechanism in improving nocturia associated with lower urinary tract symptoms/benign prostatic hyperplasia. Neurourol Urodyn. 2010; 29(7): 1276-81[DOI][PubMed]
  • 8. Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, et al. Prevention and early detection of prostate cancer. Lancet Oncol. 2014; 15(11): 484-92[DOI][PubMed]
  • 9. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008; 15(1): 3866-71[PubMed]
  • 10. Bashir MN. Epidemiology of Prostate Cancer. Asian Pac J Cancer Prev. 2015; 16(13): 5137-41[PubMed]
  • 11. Tolou-Ghamari Z. Antiepileptic drugs (AEDs) polypharmacy could lead to buried pharmacokinetic interactions due to CYP450. Drug Metab Lett. 2012; 6(3): 207-12[PubMed]
  • 12. Tolou-Ghamari Z, Mehvari-Habibabadi J, Palizban A. Evidence-Based Pharmacotherapy of Epilepsy. . Archives of Neuroscience. 2015; 2(1)
  • 13. Tolou-Ghamari Z. Efficacy and Toxicity of Rituximab in Multiple Sclerosis. Arch Neurosci. 2016; 3(1)
  • 14. Tolou-Ghamari Z, Mortazavi M, Palizban AA, Najafi MR. The investigation of correlation between Iminoral concentration and neurotoxic levels after kidney transplantation. Adv Biomed Res. 2015; 4: 59[DOI][PubMed]
  • 15. Tolou-Ghamari Z. Preliminary Evidence-Based Pharmacotherapy of Mitoxantrone for Multiple Sclerosis in an Iranian Population. Thrita. 2015; 4(3)
  • 16. Izumi K, Mizokami A, Lin WJ, Lai KP, Chang C. Androgen receptor roles in the development of benign prostate hyperplasia. Am J Pathol. 2013; 182(6): 1942-9[DOI][PubMed]
  • 17. Gurel B, Lucia MS, Thompson IM, Goodman PJ, Tangen CM, Kristal AR, et al. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2014; 23(5): 847-56[DOI][PubMed]
  • 18. Dunn CJ, Matheson A, Faulds DM. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging. 2002; 19(2): 135-61[PubMed]
  • 19. Zhong C, Wen W, Xia S. [Cost and effectiveness analysis of treatments for benign prostatic hyperplasia]. Zhonghua Yi Xue Za Zhi. 2016; 96(4): 289-92[DOI][PubMed]
  • 20. Yu YD, Kang MH, Choi CI, Shin HS, Oh JJ, Park DS. Clinical efficacy of combination therapy with an alpha blocker and low-dose sildenafil on post-therapy lower urinary tract symptoms after low-dose-rate brachytherapy for prostate cancer. World J Urol. 2016; 34(9): 1269-74[DOI][PubMed]
  • 21. Shim SR, Kim JH, Chang IH, Shin IS, Hwang SD, Kim KH, et al. Is Tamsulosin 0.2 mg Effective and Safe as a First-Line Treatment Compared with Other Alpha Blockers?: A Meta-Analysis and a Moderator Focused Study. Yonsei Med J. 2016; 57(2): 407-18[DOI][PubMed]
  • 22. Dimitropoulos K, Gravas S. Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia. Ther Adv Urol. 2016; 8(1): 19-28[DOI][PubMed]
  • 23. Chan R, Munoz A, Wenker EP, Whipple M, Miles B, Boone TB. Solifenacin and Tamsulosin Combination Therapy Decreases Urine Nerve Growth Factor/Creatinine Levels in Men. Urology. 2016; 91: 150-3
  • 24. Choi JD, Kim JH, Ahn SH. Transitional Zone Index as a Predictor of the Efficacy of alpha-Blocker and 5alpha-Reductase Inhibitor Combination Therapy in Korean Patients with Benign Prostatic Hyperplasia. Urol Int. 2016; 96(4): 406-12[DOI][PubMed]
  • 25. Carrero-Lopez VM, Cozar-Olmo JM, Minana-Lopez B. Benign prostatic hyperplasia and lower urinary tract symptoms. A review of current evidence. Actas Urol Esp. 2016; 40(5): 288-94
  • 26. Fusco F, Palmieri A, Ficarra V, Giannarini G, Novara G, Longo N, et al. alpha1-Blockers Improve Benign Prostatic Obstruction in Men with Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis of Urodynamic Studies. Eur Urol. 2016; 69(6): 1091-101[DOI][PubMed]
  • 27. Hayashi T, Takeya M, Nakamura K, Matsuoka K. Effects of Silodosin and Tamsulosin on the Seminal Vesicle Contractile Response. Low Urin Tract Symptoms. 2016; 8(1): 55-61[DOI][PubMed]
  • 28. Takeshita H, Moriyama S, Arai Y, Washino S, Saito K, Chiba K, et al. Randomized Crossover Comparison of the Short-Term Efficacy and Safety of Single Half-Dose Silodosin and Tamsulosin Hydrochoride in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Low Urin Tract Symptoms. 2016; 8(1): 38-43[DOI][PubMed]
  • 29. Ahmed AF. Sonographic Parameters Predicting the Outcome of Patients With Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treated With Alpha1-Adrenoreceptor Antagonist. Urology. 2016; 88: 143-8[DOI][PubMed]
  • 30. Radman M, Mirhoseini H, Rezahosseini O, Panahi A, Bidaki R, Jamali-Paghale M. Comparison of Urinary Symptoms in Patients with Benign Prostatic Hyperplasia after Prostatectomy for Prostates weighted more and less than 50 Grams. ZJRMS. 2014; 16(1): 102
  • 31. Tolou Ghamari Z, Mehavari Habibabadi J, Palizban AA. Evidence-Based Pharmacotherapy of Epileps. Arch Neurosci. 2015; 2(1)[DOI]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments